coadministered cagrilintide and semaglutide in adults with overweight or obesity 1 CagriSema 2.4 mg / 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blüher M, Osorto Contreras CK, et al. Efficacy and safety of co-administered
Description
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
01163-7/asset/f29611d8-43e0-475b-8d92-bab260b93b12/main.assets/gr2_lrg.jpg)
Transform your health with our personalized weight loss programs

Explore the clinical evidence, how rapid weight loss triggers telogen effluvium, and what to do if you notice shedding during treatment.
Think about building small but powerful meals: Protein +

PlexusDx compounded semaglutide injections start at $149/month with personalized dosing to match your metabolism

Studies confirm its effectiveness, making it a promising solution, even amidst menopausal weight challenges
